Human papillomavirus vaccines: Who will pay, who will receive, when to administer?

Ethnicity and Disease

Volumn 17, Issue 2, 2007, Pages

  Saslow, Debbie ^a   Wheeler, Cosette M ^b  

^a AMERICAN CANCER SOCIETY   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer disparities; Cervical cancer; Genital precancers; HPV vaccine; Human Papillomavirus (HPV); Vaccine financing

Indexed keywords

WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CONFERENCE PAPER; DRUG COST; DRUG INDICATION; FEMALE; FUNDING; HEALTH CARE POLICY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; MONEY; PRECANCER; RISK REDUCTION; TREATMENT INDICATION; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; CHILD; FEMALE; FINANCIAL SUPPORT; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 34447526540     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1): 43-66.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999;189(1):12-19.
3. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995:87(11):796-802.
4. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89(1): 101-105.
5. Weinstock H, Berman S, Cates WJr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36(1):6-10.
6. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997; 102(5A):3-8.
7. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12):1158-1171.
8. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218-226.
9. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004;364(9446):1678-1683.
10. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731-738.
11. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354(9172):20-25.
12. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1): 76-84.
13. Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children - United States, 1990-1998. MMWR. 1999;48:243-248.
14. Hinman AR, Orenstein WA, Rodewald L. Financing immunizations in the United States. Clin Infect Dis. 2004;38(10):1440-1446.
15. Centers for Disease Control and Prevention. 2006. Fiscal Year 2006 Congressional Justification of Estimates for Appropriation Committee. Available at http://www.cdc.gov/fmo/ FY2006CDCCJ.pdf. Accessed December 29, 2006.
16. Centers for Disease Control and Prevention. 2005. Childhood vaccine supply policy - public sector. Available at http://www.cdc. gov/nip/vfc/ st_immz_proj/data/vacc_supply_ public_2005.ppt. Accessed December 29, 2006.
17. Institute of Medicine. Financing Vaccines in the 21st Century: Assuring Access and Availability. Available at http://www.iom.edu/ems/ 3809/4667/14451.aspx. August 2003.
18. Rosenbaum S, Stewart A, Cox M, Mitchell S. The Epidemiology of US Immunization Law: Mandated Coverage of Immunizations Under State Health Insurance Laws. Washington, DC: George Washington University Medical Center, Center for Health Services Research and Policy; 2003.
19. Davis MM, Ndiaye SM, Freed GL, Kim CS, Clark SJ. Influence of insurance status and vaccine cost on physicians' administration of pneumococcal conjugate vaccine. Pediatrics. 2003;112(3 Pt 1):521-526.
20. Davis MM, Zimmerman JL, Wheeler JR, Freed GL. Childhood vaccine purchase costs in the public sector: past trends, future expectations. Am J Public Health. 2002;92 (12):1982-1987.
21. Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):27-48.
22. Abma JC, Martinez GM, Mosher WD, Dawson BS. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. Vital Health Stat 23.2004(24): 1-48.
23. Grunbaum JA, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2003. MMWR Surveill Summ. 2004; 53(2):1-96.
24. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285(23):2995-3002.
25. Handal GA. Adolescent immunization. Adolesc Med. 2000;11(2):439-452.
26. Centers for Disease Control and Prevention. Ten great public health achievements-United States, 1900-1999. JAMA. 1999;281(16):1481.
27. Klish S, Wang W, Linton L, Ross S, Fink N. Vaccination coverage among adolescents 1 year before the institution of a seventh grade school entry vaccination requirement - San Diego, Calironia, 1998. MMWR Morb Mortal Wkly Rep. 2000;49(5):101-211.
28. Selden TM, Banthin JS, Cohen JW. Medicaid's problem children: eligible but not enrolled. Health Aff (Millwood). 1998;17(3):192-200.
29. MacKay A, Fingerhut L, Duran C. Adolescent Health Chartbook Health United States, 2000. Hyattsville, Md: National Center for Health Statistics; 2000.
30. Mast EE, Mahoney FJ, Alter MJ, Margolis HS. Progress toward elimination of hepatitis B vitus transmission in the United States. Vaccine. 1998;16(Suppl):S48-S51.
31. Centers for Disease Control and Prevention. Immunization of adolescents. Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Recomm Rep. 1996;45(RR-13):1-16.
32. Middleman AB, Rosenthal SL, Rickert VI, Neinstein L, Fishbein DB, D'Angelo L. Adolescent immunizations: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;38(3):321-327.
33. Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in US incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004;101(5):1051-1057.
34. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-31.
35. Seeff LC, McKenna MT. Cervical cancer mortality among foreign-born women living in the United States, 1985 to 1996. Cancer Detect Prev. 2003;27(3):203-208.
36. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the scteening process. J Natl Cancer Inst. 2005;97:675-683.
37. Newmann SJ, Garner EO. Social inequities along the cervical cancer continuum: a structured review. Cancer Causes Control. 2005;16:63-70.
38. Jacob M, Bradley J, Barone MA. Human papillomavirus vaccines: what does the future hold for preventing cervical cancer in resource-poor settings through immunization programs? Sex Transm Dis. 2005;32:635-640.